Indian Phosphate (IPHL)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at a P/E of 9.99 with a PEG of 0.12, statistically cheap if recent growth persists.
• Profit growth of 156.17% alongside sales growth of 16.52% shows strong operating leverage.
• Piotroski F-Score of 7/9 suggests broadly improving fundamentals.
• Promoter holding of 72.99% aligns management with minority shareholders.
• Stock is near the lower end of its 52-week range, offering a potential margin of safety if earnings hold.

Concerns

• Latest quarter net margin is only about 2% (₹10 Cr profit on ₹499 Cr sales), leaving little room for error.
• ROCE of 8.51% is modest and does not signal a durable competitive moat.
• Critical data missing: book value, ROE, debt/equity, and FairStock Score, so balance-sheet safety cannot be assessed.
• No dividend; also, the price is down roughly 30% from the 52-week high of ₹76, suggesting market skepticism.

AI Analysis

At ₹53.35, Indian Phosphate trades at 9.99 times earnings, and a PEG of 0.12 looks like a gift if the 156.17% profit growth can continue. But Graham taught me to focus on quality and durability of earnings, not just the multiple. The latest quarter tells the real story: ₹499 Cr of sales produced only ₹10 Cr of net profit, a margin of about 2%. That is an extraordinarily thin cushion. A small rise in input costs or a dip in prices can wipe out profits. The share price has fallen from ₹76 to around ₹53 even with profit growth, suggesting the market already doubts this level of profitability. There are positives: sales grew 16.52%, profit grew 156.17%, and the Piotroski F-score of 7/9 points to improving fundamentals. Promoter holding of 72.99% aligns interests, and the company has real scale — a single reported quarter of ₹499 Cr is far larger than the entire ₹137 Cr market capitalisation. Yet ROCE is only 8.51%, not the hallmark of a wide-moat compounding business. Without book value, ROE, or debt-equity data, I cannot run a Graham balance-sheet test. Insufficient data is itself a red flag. I would treat this as a cyclical, not a franchise. The low P/E and PEG are attractive only if the thin 2% margin is sustainable and can expand. With no dividend, the investor must depend entirely on earnings growth and eventual price realisation. I would demand more margin history and proof of a strong balance sheet before putting this into a value portfolio. A cheap-looking phosphate company can become a value trap if the profit cycle turns.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer